Summary
37 consecutive, previously untreated patients with advanced multiple myeloma (16 patients Stage II, 21 patients Stage III) were treated with a five drug regimen consisting of carmustine, melphalan, vincristine, cyclophosphamide and prednisolone (M-2-protocol) in a prospective manner. Remission was achieved in 24 patients (65%). The median time to remission was 10 weeks, the median duration of remission 15,3 months. Median survival time from the onset of treatment was 24 months for all patients. Responding patients have a projected 65% three year survival. Median survival in non-responders was 10 months. 8 patients died during the first year of treatment. These results do not confirm the favourable results with this drug combination obtained in a previous trial. The discrepancy may be explained by a higher proportion of poor risk patients in the present study.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alberts DS, Durie GBM, Salmon SE (1977) Treatment of multiple myeloma in remission with anticancer drugs having cell specific characteristics. Cancer Treat Rep 61: 381–388
Alexanian R (1980) Treatment of multiple myeloma. Acta Haematol (Basel) 63: 237–240
Alexanian R, Balcerak S, Bonnet JD, Gehan EA, Haut A, Hewlett JS, Monto RW (1975) Prognostic factors in multiple myeloma. Cancer 36: 1192
Alexanian R, Bergsagel DE, Migliore DJ, Vaughn WK, Howe CD (1968) Melphalan therapy for plasma cell myeloma. Blood 31: 1–10
Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, Stuckey WJ, Wilson HE (1969) Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 208: 1680
Alexanian R, Salmon SE, Bonnet J, Gehan E, Haut A, Weick J (1977) Combination therapy for multiple myeloma. Cancer 40: 2765
Bergsagel DE, Bailey AJ, Langely GR, McDonald RN, White DF, Miller AB (1979) The chemotherapy of plasma cell myeloma and the incidence of acute leukemia. N Engl J Med 301: 743
Case D, Lee BJ (1977) Improved survival times in multiple myeloma treated with melphalan, prednisolone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med 63: 897
Chronic Leukemia-Myeloma Task Force (1973) Proposed guidlines for clinical studies. Cancer Chemother Rep 4: 145
Cohen HJ, Silberman HR, Larsen WE, Johnson L, Bartolucci AA, Durant JR (1979) Combination chemotherapy with intermittent 1-3-Bis(2-Chloroethyl) 1-Nitrosourea (BCNU), cyclophosphamide, and prednisolone for multiple myeloma. Blood 54: 824
Cornwell GG, Pajak TF, Kochwa S, McIntyre OR, Glowienky LP, Brunner K, Rafla S, Silver RT, Cooper MR, Henderson E, Kyle RA, Haurani FI, Cuttner J (1982) Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisolone in the treatment of multiple myeloma. Cancer 50: 1669–1675
Cutler SJ, Young JL (1975) The third national cancer survey: incidence data. Natl Cancer Inst Monogr 41
Dawson AA, Ogston D (1971) Factors influencing the prognosis in myelomatosis. Postgrad Med J 47: 635
Drewinko B, Alexanian R (1977) The changing growth kinetics of multiple myeloma. Blood [Suppl] 150: 145
Durie GB, Russel DH, Salmon SE (1980) Reappraisal of plateau phase in myeloma. Lancet II: 65–67
Durie GBM, Salmon SE (1975) A clinical staging system for multiple myeloma. Cancer 36: 842
Harley JB, Pojak TF, McIntyre OR, Kochwa S, Cooper MR, Coleman M, Cuttner J (1979) Improved survival of increased risk myeloma patients in combined triple alkylating agent therapy: A study of the CALBG. Blood 54: 13–22
Kyle RA (1983) Long-term survival in multiple myeloma. N Engl J Med 308: 314–316
Ludwig H, Fritz E, Friedl HP (1982) Epidemiologic and age-dependent data on multiple myeloma in Austria. J Natl Cancer Inst 68: 729
Miller S, Perotta A (1979) Multiple myeloma: results with the M-2 protocol in a community hospital. J Am Osteopathol Assoc 78: 857
Oken MM, Tsiatis A, Abramson N, Glick J (1984) Comparison of standard (MP) with intensive (VBMCP) therapy for the treatment of multiple myeloma (MM). Proc Am Soc Clin Oncol 3: 270
Salmon SE (1976) Nitrosoureas in multiple myeloma. Cancer Treat Rep 60: 789
Salmon SE, Alexanian R, Dixon D (1979) Non-cross resistant combination chemotherapy improves survival in multiple myeloma. Blood [Suppl] 54: 207 a
Salmon SE, Dixon D (1981) Addition of levamisole to chemotherapy improves survival in multiple myeloma. Blood [Suppl] 58: 168 a
Southwest Oncology Study Group (1975) Remission maintenance therapy for multiple myeloma. Arch Intern Med 135: 147
Tirelli U, Crivellari D, Carbone A, Veronesi A, Galligioni E, Trov'o MG, Tumolo S, Grigoletto E (1982) Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). Cancer Treat Rep 66: 1971
Author information
Authors and Affiliations
Additional information
Institut für Klinische Chemie und Laboratoriumsdiagnostik
Rights and permissions
About this article
Cite this article
Gössinger, H., Bettelheim, P., Neumann, E. et al. Efficacy of the M-2 protocol in previously untreated patients with advanced multiple myeloma. Blut 49, 383–388 (1984). https://doi.org/10.1007/BF00319886
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00319886